
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT
ON-MARKET SHARE REPURCHASE

This announcement is made by InSilico Medicine Cayman TopCo (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company wishes to announce that the Company has decided to repurchase shares of the Company (the "**Shares**") in the open market on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") from time to time for an aggregate amount of up to HK$500 million (the "**Share Repurchase**") pursuant to the general mandate (the "**Repurchase Mandate**") granted to the Directors and approved by the shareholders of the Company (the "**Shareholder(s)**") at the annual general meeting (the "**AGM**") held on June 2, 2026. The term of the Repurchase Mandate shall commence from the date of the AGM until the earliest of the following dates: (i) the conclusion of the next annual general meeting of the Company; (ii) the revocation or variation of the authority given under the Repurchase Mandate by ordinary resolution passed by the Shareholders in a general meeting; or (iii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company (the "**Articles of Association**") or any applicable laws to be held. Details of the Repurchase Mandate, together with the explanatory statement in connection therewith, are set out in the AGM circular of the Company dated April 28, 2026.

The Board shall conduct the Share Repurchase by exercising its powers granted to the Directors under the Repurchase Mandate and in compliance with the Articles of Association, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Act (As Revised) of the Cayman Islands and all applicable laws and regulations to which the Company is subject. The Company intends to finance the proposed Share Repurchase with its own financial resources (other than the proceeds raised from its global offering).

The Board considers that the current trading price of the Shares undervalues the intrinsic value and development prospects of the Company, and that the Share Repurchase will enhance Shareholder value. The Board believes that the Share Repurchase demonstrates the Company's confidence in its business outlook and prospects and will, in the long term, benefit the Company and create value for its Shareholders. The Board believes that the Company has sufficient financial resources to implement the Share Repurchase while maintaining a solid financial position and without adversely affecting its operations.

As of the date of this announcement, the Company has not repurchased any Shares under the Repurchase Mandate. The proposed Share Repurchase shall not result in the number of Shares held by the public falling below the relevant minimum percentage prescribed by the Listing Rules.

Shareholders and potential investors should note that the implementation of the on-market Share Repurchase by the Company will be subject to market conditions and will be conducted at the absolute discretion of the Board and/or its authorized person(s). There is no assurance as to the timing, quantity or price of any repurchases or whether the Company will repurchase any Shares at all. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, October 30, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive Directors; Mr. Chuen Yan Leung, Ph.D. as non-executive Director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive Directors.